Aims The study was carried out in order to assess the effects of gender and
the use of oral contraceptives (OCs) on CYP2D6 and CYP2C19 activities in h
ealthy volunteers.
Methods Six hundred and eleven Caucasian volunteers (330 males and 281 fema
les; age range 18-49 years) were phenotyped with respect to CYP2D6 and CYP2
C19 by means of the probe drugs dextromethorphan and mephenytoin, respectiv
ely. Extensive metabolisers were selected for this study.
Results The median dextromethorphan/dextrorphan metabolic ratio in non-OC u
sing females was significantly lower than in males (0.067 vs 0.080; P=0.033
) (mean difference in In dextromethorphan/dextrorphan metabolic ratio 0.023
, 95% CI 0.03-0.43). For the mephenytoin S/R ratio, no such difference was
observed. However, OC using females had a significantly higher median mephe
nytoin S/R ratio than non-OC using females (0.230 vs 0.090; P<0.001) (mean
difference in In mephenytoin S/R ratio 0.082, 95% CI 0.60-1.04). Moreover,
females using combined OCs had a significantly higher median ratio than fem
ales using OCs with progestins only (median 0.258 vs 0.135; P=0.008) (mean
difference in In mephenytoin S/R ratio 0.82, 95% CI 0.21-1.34).
Conclusions Given certain assumptions, the study indicates that females in
the fertile age have a slightly higher CYP2D6 activity compared with males.
There was no evidence of a gender difference in CYP2C19 activity. The use
of combined OCs reduces the activity of CYP2C19, an effect that seems to be
related to the ethinyloestradiol component.